These analyses indicated a notable correlation between a high TSPAN13 expression level and a reduced overall survival time (OS) in patients, suggesting poorer outcomes, in both the TCGA and Gravendeel GBM cohorts (Fig 6e and 6f). The gene discussed is TSPAN13; the disease is glioblastoma.